PEDIATRICS Vol. 81 No. 4 April 1988, pp. 485-497
This Article
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kappas, A.
Right arrow Articles by Valaes, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kappas, A.
Right arrow Articles by Valaes, T.

Sn-Protoporphyrin Use in the Management of Hyperbilirubinemia in Term Newborns With Direct Coombs-Positive ABO Incompatibility

Attallah Kappas MD1, George S. Drummond PhD1, Thomais Manola MD1, Sophia Petmezaki MD1, and Timos Valaes MD1

1 From The Rockefeller University Hospital, New York, and the Metera Maternity Hospital, Athens

In two separate studies, in which two different treatment regimens of Sn-protoporphyrin were used, a total of 69 control and 53 treated infants were studied to determine whether this potent inhibitor of the enzyme, heme oxygenase, could ameliorate the severity of the hyperbilirubinemia which develops in term babies with direct Coombs-positive ABO incompatibility. The results indicate that Sn-protoporphyrin can, in appropriate doses, moderate the postnatal rate of increase of plasma bilirubin levels and diminish the intensity of hyperbilirubinemia in treated babies. In addition, a decreased use of phototherapy in Sn-protoporphyrin-treated infants was observed. No rebound hyperbilirubinemia was detected during the six- to eight-day period after Sn-protoporphyrin administration. The plasma clearance (tfrac12) of Sn-protoporphyrin was much faster in newborns than in adults (approximately 1.6 hours v 3.5 hours, respectively). The incidence of clinical side effects in the 53 Sn-protoporphyrin-treated infants was limited to the development of transient erythema during the use of concurrent phototherapy in two babies. In both infants this reaction subsided completely without sequelae. The use of Sn-protoporphyrin or related synthetic heme analogues to diminish the severity of hyperbilirubinemia in newborn infants merits further study because inhibition of the rate-limiting enzyme in the catabolism of heme to bilirubin may prove to be a useful therapeutic approach in the clinical management of neonatal hyperbilirubinemia, especially in settings in which, for social or economic reasons, other treatment modalities are not available.

Key Words: Sn-protoporphyrin • newborn • jaundice • hyperbilirubinemia • heme oxygenase • ABO incompatibility

Submitted on August 13, 1987
Accepted on November 17, 1987




This article has been cited by other articles:


Home page
 Pharmacol. Rev.Home page
N. G. Abraham and A. Kappas
Pharmacological and Clinical Aspects of Heme Oxygenase
Pharmacol. Rev., March 1, 2008; 60(1): 79 - 127.
[Abstract] [Full Text] [PDF]

Home page
 NeoReviewsHome page
R. J. Wong, V. K. Bhutani, H. J. Vreman, and D. K. Stevenson
Pharmacology Review: Tin Mesoporphyrin for the Prevention of Severe Neonatal Hyperbilirubinemia
NeoReviews, February 1, 2007; 8(2): e77 - e84.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
A. Kappas
A Method for Interdicting the Development of Severe Jaundice in Newborns by Inhibiting the Production of Bilirubin
Pediatrics, January 1, 2004; 113(1): 119 - 123.
[Full Text] [PDF]

Home page
 PediatricsHome page
A. Kappas, G. S. Drummond, and T. Valaes
A Single Dose of Sn-Mesoporphyrin Prevents Development of Severe Hyperbilirubinemia in Glucose-6-Phosphate Dehydrogenase-Deficient Newborns
Pediatrics, July 1, 2001; 108(1): 25 - 30.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
T. R. Grover, R. L. Rairigh, J. P. Zenge, S. H. Abman, and J. P. Kinsella
Inhaled carbon monoxide does not cause pulmonary vasodilation in the late-gestation fetal lamb
Am J Physiol Lung Cell Mol Physiol, April 1, 2000; 278(4): L779 - L784.
[Abstract] [Full Text] [PDF]

Home page
 Anesth. Analg.Home page
X. Li and J. D. Clark
The Role of Heme Oxygenase in Neuropathic and Incisional Pain
Anesth. Analg., March 1, 2000; 90(3): 677 - 682.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
Y. Liu and P. R. Ortiz de Montellano
Reaction Intermediates and Single Turnover Rate Constants for the Oxidation of Heme by Human Heme Oxygenase-1
J. Biol. Chem., February 25, 2000; 275(8): 5297 - 5307.
[Abstract] [Full Text] [PDF]

Home page
 NeoReviewsHome page
C. Hammerman and M. Kaplan
Recent Developments in the Management of Neonatal Hyperbilirubinemia
NeoReviews, February 1, 2000; 1(2): e19 - 24.
[Full Text]

Home page
 Clin. Chem.Home page
R. F. Labbe, H. J. Vreman, and D. K. Stevenson
Zinc Protoporphyrin: A Metabolite with a Mission
Clin. Chem., December 1, 1999; 45(12): 2060 - 2072.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
J. C. Martinez, H. O. Garcia, L. E. Otheguy, G. S. Drummond, and A. Kappas
Control of Severe Hyperbilirubinemia in Full-term Newborns With the Inhibitor of Bilirubin Production Sn-Mesoporphyrin
Pediatrics, January 1, 1999; 103(1): 1 - 5.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
T. Valaes, G. S. Drummond, and A. Kappas
Control of Hyperbilirubinemia in Glucose-6-Phosphate Dehydrogenase-deficient Newborns Using an Inhibitor of Bilirubin Production, Sn-Mesoporphyrin
Pediatrics, May 1, 1998; 101 (5): e1 - e1.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
A. S. Paller, L. R. Eramo, E. E. Farrell, D. D. Millard, P. J. Honig, and B. B. Cunningham
Purpuric Phototherapy-induced Eruption in Transfused Neonates: Relation to Transient Porphyrinemia
Pediatrics, September 1, 1997; 100(3): 360 - 364.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
Y. Liu, P. Moenne-Loccoz, T. M. Loehr, and P. R.O. de Montellano
Heme Oxygenase-1, Intermediates in Verdoheme Formation and the Requirement for Reduction Equivalents
J. Biol. Chem., March 14, 1997; 272(11): 6909 - 6917.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
J. D. Lutton, N. G. Abraham, G. S. Drummond, R. D. Levere, and A. Kappas
Zinc porphyrins: Potent inhibitors of hematopoieses in animal and human bone marrow
PNAS, February 18, 1997; 94(4): 1432 - 1436.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
Y. Liu, L. K. Lightning, H.-w. Huang, P. Moenne-Loccoz, D. J. Schuller, T. L. Poulos, T. M. Loehr, and P. R. Ortiz de Montellano
Replacement of the Distal Glycine 139 Transforms Human Heme Oxygenase-1 into a Peroxidase
J. Biol. Chem., October 27, 2000; 275(44): 34501 - 34507.
[Abstract] [Full Text] [PDF]